20:58 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Oxford BioDynamics reports data for predicting inadequate responders to methotrexate

Oxford BioDynamics plc (LSE:OBD) and colleagues reported that the presence of a five-marker Chromosome Confirmation Signature (CCS) in the blood of patients with early rheumatoid arthritis as detected by the company's EpiSwitch epigenetic biomarker platform...
01:19 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Age-related macular degeneration (AMD) Patient sample, cell culture and mouse studies suggest inhibiting cGAS, CASP4, GSDMD, IFNB1, IFNAR1, IRF3 or STAT2 could help treat geographic atrophy. In tissue samples from patients, levels of cGAS, GSDMD...
20:05 , Nov 6, 2017 |  BC Extra  |  Preclinical News

Team identifies new targets to treat myocardial infarction

In a paper published Monday in Nature Medicine, researchers from Massachusetts General Hospital and colleagues identified the mechanism behind an elevated immune response after myocardial infarction and suggested interferon regulatory factor 3 (IRF3), interferon alpha/beta...
19:51 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Myocardial infarction (MI) Mouse studies suggest inhibiting IRF3, IFNAR1, or cGAS could help treat MI. In infarcted heart tissue from a mouse model of MI, IRF3 expression was higher than in heart tissue from normal...
01:21 , Jan 12, 2017 |  BC Innovations  |  Translation in Brief

Give me a break

In 2013, two groups introduced the paradoxical and, at the time, controversial hypothesis that blocking antiviral cytokine signals can help clear chronic infections by reinvigorating T cells exhausted from non-stop inflammation. One of those groups...
00:50 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Mouse studies suggest inhibiting IFNAR2 or IFNAR1 could help treat HIV1 infection. In a humanized mouse model of chronic HIV infection, an anti-IFNAR2 mAb decreased plasma viral load and levels of exhaustion markers such...
20:18 , Jan 5, 2017 |  BC Innovations  |  Translation in Brief

Insect protection

By forcing an insect virus that does not infect humans to express clinically relevant viral antigens, a Texas team is creating vaccines that are as immunogenic as live pathogens, without the danger of causing disease....
20:33 , Nov 9, 2016 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts An IFNAR1-knockout mouse model of HAV infection could help identify targets and test therapies for the infection. Mice genetically deleted IFNAR that were infected with HAV, recapitulated the viremia, liver pathology and...
07:00 , May 12, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Mice with knockout of interferon-related genes as models of Zika infection

Disease models TECHNOLOGY: Transgenics and knockouts Two mouse models with knockout of interferon-related genes could be useful for screening therapies to treat Zika infection. In mice with knockout of interferon regulatory factor 3 (IRF3), IRF5 and IRF7,...
07:00 , Mar 31, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interferon α/β receptor 1 (IFNAR1); tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Infectious disease INDICATION: Acute lung injury; respiratory distress syndrome (RDS) Cell culture and mouse studies suggest that combining inhibitors of IFNAR1 and TRAIL could help treat acute respiratory distress syndrome (ARDS) and other types of acute lung...